¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"erythrocyte antigen test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • acceptance test
    Àμö°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • anticholinesterase test
    Ç×Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • aptitude test
    Àû¼º°Ë»ç
  • articulation test
    ¹ßÀ½°Ë»ç
  • association test
    ¿¬»ó°Ë»ç
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • autohemolysis test
    ÀÚ°¡¿ëÇ÷°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • adsorption test
    ÈíÂø½ÃÇè, ºÎÂø°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • soluble antigen
    ¼ö¿ë¼ºÇ׿ø
  • somatic antigen
    ü¼¼Æ÷Ç׿ø, ±ÕüÇ׿ø
  • specific antigen
    ƯÀÌÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • thymus-dependent antigen
    °¡½¿»ùÀÇÁ¸Ç׿ø
  • thymus-independent antigen
    °¡½¿»ùºñÀÇÁ¸Ç׿ø
  • transplantation antigen
    À̽ÄÇ׿ø
  • tumor antigen
    Á¾¾çÇ׿ø
  • type specific antigen
    ÇüƯÀÌÇ׿ø
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • T cell antigen receptor
    Ƽ¼¼Æ÷Ç׿ø¼ö¿ëü
  • abrasion test
    ¸¶¸ê½ÃÇè
  • absorption test
    Èí¼ö½ÃÇè, Èí¼ö°Ë»ç
  • acceptance test
    Àμö°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • V antigen
    V Ç׿ø
  • Vi antigen
    ViÇ׿ø.
  • Wright Antigen
    ¶óÀÌÆ®Ç׿ø
  • a antigen
    A Ç׿ø
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø, ±ÙÁ¢Ç׿ø(ÐÎïÈù÷ê«).
  • analysis, antigen
    Ç׿øºÐ¼®
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen competition
    Ç׿ø°æÀï.
  • antigen detection
    Ç׿ø°ËÃâ
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö(ù÷ê«üªß¤ßÈâ¦).
  • antigen drift
    Ç׿ø¼Òº¯ÀÌ.
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen mimicry
    Ç׿øÀ¯»ç¼º.
  • antigen modification
    Ç׿øº¯Çü.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Morner's test
    ¸ð³Ê ½ÃÇè(ãËúÐ)
  • murexide test
    ¹Â·¡½Ãµå°Ë»ç(ËþÞÛ)
  • patch test
    ÆÐÄ¡½ÃÇè(ãËúÐ)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phenolsulfonphthalein test
    Æä³î¼³ÆùÅ»·¹ÀÎ ½ÃÇè(ãËúÐ)
  • phenylalanine load test
    Æä´Ò¾Ë¶ó´Ñ ºÎÇϽÃÇè(ݶùÃãËúÐ)
  • phenylalanine tolerance test
    Æä´Ò¾Ë¶ó´Ñ ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • PSP test
    (å²) Phenolsulfonphthalein test
  • radioactive antibody test
    ¹æ»ç¼º Ç×ü ½ÃÇè(°ËÁ¤)(Û¯ÞÒàõù÷ô÷ãËúÐ(ËþïÒ))
  • resorcinol test
    ¸®Á¶¸£½Ã³î ½ÃÇè(ãËúÐ)
  • reversible boundary spreading test
    °¡¿ª °æ°è ºÐ»ê ½ÃÇè(ʦæ½ÌÑÍ£ÝÂߤãËúÐ)
  • Rice test
    ¶óÀ̽º ½ÃÇè(ãËúÐ)
  • ring test
    °í¸®½ÃÇè(ãËúÐ)
  • Rothera's test
    ·ÎÅ×¶ó ½ÃÇè(ãËúÐ)
  • Schiff's test
    ½¬ÇÁ ½ÃÇè(ãËúÐ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
TT tablet triturate; tactile tension; tendon transfer; test tube; testicular torsion; tetanus toxin; te...
TTT thymol turbidity test; tolbutamide tolerance test; total twitch time; tuberculin tine test
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
AA abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];...
CA anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
BDT Basophil Degranulation Test
BVRT Benton Visual Retention Test
BNT Boston Naming Test
BHT Breath hydrogen test
BOTMP Bruininks Oseretsky Test of Motor Proficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Becker's test
    º£Ä¿ ½ÃÇè
  • Bekhterev's test
    º£Å©Å×·¹ºê ½ÃÇè
  • Benedict's test
    º£³×µñÆ® ½ÃÇè
  • Bernstein test
    º£¸¥½ºÅ¸ÀÎ ½ÃÇè
  • beta test
    º£Å¸ ½ÃÇè
  • bethanechol supersensitivity test
    º£Å¸³×ÄÝ °ú¹Î¹ÝÀÀ °Ë»ç
  • Bial's test
    ºñ¾Ë ½ÃÇè
  • bicarbonate titration test
    Áßź»ê¿° ÀûÁ¤ ½ÃÇè
  • Bielschowsky head-tilting test
    ºô¼î½ºÅ° µÎºÎ °æ»ç ½ÃÇè
  • bile solubility test
    ´ãÁó ¿ëÇØ ½ÃÇè
  • bilirubin test
    ºô¸®·çºó ½ÃÇè
  • binaural distorted speech test
    ¾çÀÌ¿ÖÈ­ ½ÃÇè
  • Binet's test
    ºñ³× ½ÃÇè
    ¼Ò¾Æ¿Í û³âÀÇ Á¤½Å ´É·ÂÀ» °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, °¢Á¾ ¿¬·É¿¡¼­ÀÇ Á¤»ó ¾Æµ¿ÀÇ ´É·Â¿¡ ÀûÇÕÇϰí Ç¥ÁØÈ­µÈ ÀÏ·ÃÀÇ Áú¹®À» ÇǰËÀÚ¿¡°Ô ÇÏ¿©, ÀÌ¿¡ ´ëÇÑ ´ë´ä¿¡ µû¶ó ÇǰËÀÚÀÇ Á¤½Å ¿¬·ÉÀ» °áÁ¤ÇÏ´Â °Í.
  • Bing test
    ºù ½ÃÇè
    Áøµ¿À½Â÷¸¦ À¯¾çµ¹±â À§¿¡ ³õ°í, ûµµ¸¦ ±³´ë·Î Æó¼âÇÏ¿´´Ù°¡ °³¹æÇÏ¿´´Ù°¡ ÇÑ´Ù. ¼Ò¸®ÀÇ ³ô°í ³·À½Àº Á¤»ó ±Í¿¡¼­ ûÃëµÇ¸ç, ¶ÇÇÑ Áö°¢½Å°æ¼º û°¢½Å°æ¼º û°¢Àå¾Ö¿¡¼­µµ µé¸®³ª, Àüµµ û°¢ Àå¾Ö¿¡¼­´Â ¼Ò¸®ÀÇ Â÷À̰¡ ¾øÀÌ µé¸°´Ù.
  • biuret test
    ¹ÙÀÌÀ¯·¿ ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
HLA-b8 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. It is in linkage disequilibrium with HLA-a1 and HLA-dr3. This explains the fact that though HLA-b8 was originally associated with several diseases, including coeliac disease, dermatitis herpetiformis, and myasthenia gravis, their association with HLA-dr3 is now considered more significant.
(12 Dec 1998)
HLA-dr1 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells.
(12 Dec 1998)
HLA-dr2 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells. It is in linkage disequilibrium with HLA-a3 and HLA-b7 and is strongly associated with goodpasture syndrome, multiple sclerosis, and narcolepsy.
(12 Dec 1998)
HLA-dr3 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells. It is in linkage disequilibrium with HLA-a1 and HLA-b8. The HLA-dr3 antigen is strongly associated with coeliac disease, grave's disease, dermatitis herpetiformis, early-age onset myasthenia gravis, systemic lupus erythematosus, juvenile diabetes, and opportunistic infections in aids.
(12 Dec 1998)
HLA-dr4 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells. It is strongly associated with rheumatoid arthritis and juvenile diabetes.
(12 Dec 1998)
HLA-dr5 antigen <immunology> Human immune-response, d-related antigen encoded by the d-locus on chromosome 6 and found on lymphoid cells. It is associated with kaposi sarcoma in aids and juvenile rheumatoid arthritis.
(12 Dec 1998)
HLA-dr6 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells.
(12 Dec 1998)
HLA-dr7 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells. It is strongly associated with coeliac disease and psoriasis vulgaris.
(12 Dec 1998)
homologous antigen <immunology> A homologous antigen is one which will attract and react with a specific antibody.
(09 Oct 1997)
self antigen <immunology> The antigens of an organisms own cells and cell products are self antigens to the immune system of that organisn.
Clones of immune cells reactive with self antigens are normally eliminated.
(18 Nov 1997)
senescent cell antigen <immunology> An antigen (62 kD) that appears on the surface of senescent erythrocytes and is immunologically cross reactive with isolated Band III protein. Seems to be recognised by an autoantibody and the immunoglobulin coated erythrocyte is then removed from circulation by cells such as Kuppfer cells of the liver that have Fc receptors. Intracellular cleavage of intact band III by a calcium activated protease, calpain, may reveal the antigen in situ.
(18 Nov 1997)
sensitised antigen The complex formed when antigen combines with specific antibody; so called because the antigen, by the mediation of antibody, is rendered sensitive to the action of complement.
(05 Mar 2000)
human leukocyte antigen <immunology> A genetic fingerprint on white blood cells and platelets, composed of proteins that play a critical role in activating the bodys immune system to respond to foreign organisms.
Acronym: HLA
(16 Dec 1997)
human lymphocyte antigen A system designation for the gene products of at least four linked loci (A, B, C, and D) and a member of subloci on the sixth human chromosome which have been shown to have a strong influence on human allotransplantation, transfusions in refractory patients, and certain disease associations; more than 50 alleles are recognised, most of which are at loci HLA-A and HLA-B; autosomal dominant inheritance.
(05 Mar 2000)
serum factor VIII antigen A test used to measure the activity of a blood clotting factor VIII (Von Willebrand factor). This test is usually used to monitor treatment of haemophilia. Abnormally low factor VIII assays may be seen in the following conditions: congenital deficiency of factor VIII (haemophilia), DIC and secondary fibrinolysis. This test may also be performed in the evaluation of Von Willebrand's disease.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á